Please login to the form below

Not currently logged in
Email:
Password:

vedolizumab

This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.

EC approves drugs for diabetes and Crohn’s disease

EC approves drugs for diabetes and Crohn’s disease

The European Commission ( EC) has approved Takeda's Entyvio ( vedolizumab) to treat adults with ulcerative colitis and Crohn's disease and Boehringer Ingelheim/Lilly's Jardiance ( empagliflozin), which adds to the growing list of treatments

Latest news

  • FDA clears Takeda's <b>vedolizumab</b> for inflammatory bowel disease FDA clears Takeda's vedolizumab for inflammatory bowel disease

    FDA clears Takeda's vedolizumab for inflammatory bowel disease. Entyvio licensed for patients who have not responded to current therapies. ... The FDA approved Entyvio ( vedolizumab) to treat adults with moderate to severe ulcerative colitis ( UC) and

  • FDA panel backs Takeda's inflammatory bowel disease drug FDA panel backs Takeda's inflammatory bowel disease drug

    FDA panel backs Takeda's inflammatory bowel disease drug. Vedolizumab on course for US approval to treat Crohn's disease and ulcerative colitis. ... Takeda's Millennium Pharmaceuticals unit took a step closer to US approval for one of its top pipeline

  • FDA grants priority review to Takeda's colitis drug FDA grants priority review to Takeda's colitis drug

    FDA grants priority review to Takeda's colitis drug. Accelerates review time for vedolizumab. ... One of Takeda's top pipeline prospects - vedolizumab for ulcerative colitis ( UC) - has been given a priority review by the US Food and Drug Administration (

  • Phase III data raise hopes for Takeda's <b>vedolizumab</b> Phase III data raise hopes for Takeda's vedolizumab

    Phase III data raise hopes for Takeda's vedolizumab. Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease. ... Data from phase III trials of Takeda's inflammatory bowel disease ( IBD) drug vedolizumab suggests the company's

  • Takeda files IBD drug <b>vedolizumab</b> in Europe Takeda files IBD drug vedolizumab in Europe

    Takeda files IBD drug vedolizumab in Europe. Potential safer alternative to TNF blockers like Remicade and Humira. ... Takeda has filed for approval in Europe of inflammatory bowel disease ( IBD) drug vedolizumab, one of its key pipeline drugs.

More from news
Approximately 6 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel ( TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel ( TAK-700),

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. We are an award-winning agency with over 30...

Latest intelligence

Online Physician Communities
M3 improves personalisation of pharma engagement with doctors
Launches new messaging service on Doctors.net.uk...
Digital Futures 2014 slide deck
Full slides, including survey data, from PMLiVE's digital pharma marketing online event...
The Chinese diabetes challenge
Marketing, communications and commercial relationships in China are full of pitfalls for the unwary, but not without great potential ...